Cellyan Biotechnology Co., Ltd

HKPD Healthcare Medical Distribution

Cellyan Biotechnology Co., Ltd’s revenue for fiscal 2026 (year ended March 2026) was $13.4 million, down 33.9% from fiscal 2025.

0.11 0.00 0.00%
Market cap
$17.1M
P/E
—
Fwd P/E
—
Dividend yield
—
F-score
3/9
Altman Z
3.39
Beneish M
−0.76
Dividend safety
n/a
Dec '22 Mar '23 Dec '23 Mar '24 Mar '25 Mar '26
Piotroski F-Score
— — — — 4 3
Altman Z-Score
— — — — 4.66 3.39
P/FCF ratio
0.00 0.00 — 0.00 0.00 0.00
Altman Z″-Score (non-manufacturers)
2.85 2.85 — 6.34 5.84 7.32
Beneish M-Score
— — — (0.49) (2.40) (0.76)
P/Operating CF
0.00 0.00 — 0.00 0.00 0.00
P/B ratio
0.00 0.00 — 0.00 0.00 0.00
Price to Tangible BV
0.00 0.00 — 0.00 0.00 0.00
EV/Sales
0.00 0.00 — 0.00 0.00 0.00
EV/EBITDA
0.00 0.00 — 0.00 0.00 0.00
EV/Operating CF
0.00 0.00 — 0.00 (0.42) 2.21
EV/FCF
0.00 0.00 — 0.00 (0.47) 5.00
Quick Ratio
1.00 1.00 0.00 1.77 2.80 3.75
Current Ratio
1.08 1.08 0.00 2.46 2.99 3.86
Net Debt/EBITDA
(0.40) (0.19) 0.00 0.49 (5.45) (0.79)
Debt/Assets
3.07% 9.13% 0.00% 16.76% 19.98% 7.34%
Debt/Equity
0.18 0.53 — 0.34 0.38 0.10
Asset Turnover
0.00 3.69 0.00 2.45 2.25 1.21
Operating CF/Net income
0.00 1.73 0.00 (0.30) (21.00) 0.66
Capex/Depreciation
— (1.59) — (0.85) (2.04) (0.49)
Interest Coverage
44.99 44.99 — 19.42 1.34 (7.48)
ROE
0.00% 253.80% 0.00% 54.96% (0.59%) (15.59%)
ROA
0.00% 29.30% 31.71% 19.49% (0.30%) (10.21%)
ROIC
395.14% 175.61% 0.00% 19.79% 2.11% (6.07%)
Return on Tangible Assets
285.77% 285.77% 26.69% 28.12% (0.46%) (12.35%)
Average Days of Receivables
59.10 59.10 0.00 108.94 92.74 319.30
Research and Development Expense of Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Selling, General and Administrative Expense of Revenue
13.50% 14.00% 0.00% 11.32% 10.91% 17.83%
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00 0.01 0.01
Share Based Compensation of Revenue
0.00% 0.00% — 0.00% 0.00% 0.00%
Graham Net Nets
0.00 0.00 — 0.00 0.00 0.00
Graham Number
0.00 0.00 — 0.00 0.00 0.00
Free Cash Flow Yield
0.00% 0.00% — 0.00% 0.00% 0.00%
Revenue per Share
0.00 1.83 — 2.27 1.99 0.82
Operating CF per Share
— 0.25 — (0.05) 0.06 (0.05)
Capex per Share
— (0.02) — (0.01) (0.02) 0.00
Free Cash Flow per Share
— 0.24 — (0.06) 0.04 (0.05)
Cash per Share
0.00 0.08 — 0.09 0.29 0.01
Shareholders Equity per Share
0.00 0.09 — 0.58 0.49 0.59
Interest Debt per Share
0.00 0.00 — 0.00 0.00 0.00
Book value per Share
0.00 0.09 — 0.58 0.49 0.59
Free Cash Flow
— 1.61 — (0.45) 0.41 (0.79)
Working Capital
0.20 0.20 4.98 4.63 5.81 9.14
Capital Expenditures
— (0.12) — (0.05) (0.15) (0.04)
Net Current Asset Value
(0.07) (0.07) 4.98 3.39 4.30 9.07
EV/EBIT
0.00 0.00 — 0.00 0.00 0.00
Capex to Sales
0.00 0.01 — 0.00 0.01 0.00
Other line items
Depreciation/Fixed assets
0.00 0.49 — 0.62 0.68 1.47
Cash ROIC
0.00% 113.28% — (7.09%) 4.19% (7.39%)
Accounts Receivable Turnover
0.00 6.18 0.00 3.35 4.01 1.59
Accounts Payable Turnover
0.00 0.00 — 8.86 11.06 8.94
Inventory Turnover
0.00 51.43 — 23.36 23.97 26.19
Average Days of Payables
0.00 57.60 — 39.37 37.15 26.48
Days of Inventory on Hand
7.10 7.10 — 25.95 11.42 10.91
Average Receivables
— 2.03 3.51 4.98 5.07 8.46
Average Payables
— — — 1.48 1.62 1.35
Average Inventory
— 0.19 — 0.56 0.75 0.46
Average Assets
— 3.41 4.19 6.82 9.04 11.13
Average Common Equity
— 0.39 — 2.42 4.62 7.29

Fold the line items

Columns are period end dates